One email a week. Catch up in five minutes.

The GammaRips weekly briefing — engine state, the latest deep-dive, and the picks on the public ledger. No firehose, no FOMO.

We Use Cookies

We use cookies to enhance your experience, analyze site traffic, and for marketing purposes. By clicking "Accept," you agree to our use of cookies. Read our Privacy Policy.

BHVN

BULL

2026-06-18

Overnight Institutional Flow Signal · Healthcare

See the 2026-06-18 Morning Briefing

Score

8/10

Move

13.2%

Flow

$2.0M

AI Trade Thesis

BHVN BULL $15C Jul 17 '26. Strong institutional options flow of $1.67M points to proactive, bullish positioning ahead of the clinical-stage biotech's impending initiation of pivotal trials for cancer, IgA nephropathy, and Graves' disease candidates by month-end. With the broader market exhibiting a calm volatility regime and the flow direction running contrary to today's slightly mixed-to-bearish scan backdrop, this is a highly focused, idiosyncratic alpha play. Entry near the underlying spot of $13.62 with a target of $17.50. Risk: clinical trial design delays or broader biotech-sector weakness.

Flow Breakdown

Call Volume

$1.7M

Put Volume

$335K

Flow Intent

DIRECTIONAL

Catalyst

Technical Breakout

More Bullish Flow · 2026-06-18

VRTX8/10 AMGN8/10 MRNA7/10 GILD7/10 SPG9/10 PLD9/10

Recommended Setup

ContractO:BHVN260717C00015000

Strike$15.00

Expiration2026-07-17

Mid Price$0.97

Contract Score9.897/10

Risk/Reward0.2:1

Delta0.42

Key Levels

Resistance$13.97

Support$11.58

Price$13.62

SMA 50 / 200$10 / $12

52W Range$7 — $24

RSI (14)71

News & Catalyst Analysis

Key Headline

Biohaven (BHVN) Climbs 12.66% Ahead of Pipeline Updates

News Summary

Biohaven (BHVN) surged +12.66% on Wednesday to close at $13.62 as investors aggressively positioned portfolios ahead of key pipeline updates. Speculators are anticipating the initiation of pivotal studies by the end of June for several cancer, IgA nephropathy, and Graves' disease candidates. The institutional options flow is highly supportive, suggesting that market participants are looking to capture upside before official clinical milestones are formally announced.

Flow Intent Analysis

The bullish options flow represents a clear, speculative pre-catalyst positioning play ahead of crucial clinical trials initiating by the end of June, rather than a protective hedge.

One email a week. Catch up in five minutes.

The GammaRips weekly briefing — engine state, the latest deep-dive, and the picks on the public ledger. No firehose, no FOMO.

How We Read This Flow

Plain-English explainers on the methodology behind signals like this one.

View all →

One email a week. Catch up in five minutes.

BHVN

Key Headline

News Summary

Flow Intent Analysis

One email a week. Catch up in five minutes.

How We Read This Flow

Why 90% of Options Traders Fail: Building Better Retail Options Trading Systems

A $19/mo Options Signal Service Review: Why Skipping Bad Days is Your Greatest Edge

What Gets Pushed to My Phone at 7:30 AM ET (Weekly Engine Recap)